Lettonie - letton - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - azitromicīns - apvalkotā tablete - 500 mg

Lettonie - letton - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - citarabīns - Šķīdums injekcijām/infūzijām - 100 mg/ml

Lettonie - letton - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - azitromicīns - apvalkotās tabletes - 500 mg

Lettonie - letton - Zāļu valsts aģentūra

pfizer spol. s.r.o., czech republic - metilprednizolons - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 40 mg

Lettonie - letton - Zāļu valsts aģentūra

teva pharma b.v., netherlands - azitromicīns - disperģējamā tablete - 500 mg

Union européenne - letton - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Union européenne - letton - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Lettonie - letton - Zāļu valsts aģentūra

sandoz d.d., slovenia - takrolims - ilgstošās darbības kapsula, cietā - 0,5 mg

Lettonie - letton - Zāļu valsts aģentūra

sandoz d.d., slovenia - takrolims - ilgstošās darbības kapsula, cietā - 1 mg

Lettonie - letton - Zāļu valsts aģentūra

sandoz d.d., slovenia - takrolims - ilgstošās darbības kapsula, cietā - 2 mg